The new materials provide an interesting overview on this ever growing market at a significant time, with biological medicines - which include biosimilar medicines - now amongst today's most important medicines. Interesting facts in the materials include:
* It is predicted that by 2016 seven of the top 10 medicines worldwide will be biologics.
* Since 2006, over 18 branded biosimilar medicines have been granted marketing authorisations in the EU.
* The introduction of biological medicines in the early 1980s revolutionised treatment for some life-threatening and rare diseases, such as cancer, diabetes, blood conditions, rheumatoid arthritis, multiple sclerosis and autoimmune disorders.
* The number of biosimilar medicines available in the
* It is recommended by the ABPI and the BIA that all biological medicines, including biosimilar medicines, should be prescribed by brand name and not by International Non-Proprietary Names (INN), to ensure accurate reporting and analysis of suspected adverse reactions.
* Automatic substitution is not appropriate for biological medicines, including biosimilar medicines. These must only be substituted under the direct supervision and with the consent of the treating physician.
Commenting on the publication of these documents, ABPI Director of Value and Access,
"A number of ABPI and BIA members are developing biosimilar medicines and we are therefore building relationships with key stakeholders at a national and local level in order to improve understanding of biological medicines, including biosimilar medicines. These new informative materials will assist in ensuring that these medicines are well understood and used appropriately for the benefit of all eligible NHS patients."
Commenting, BIA Chief Executive Officer,
"Biological medicines, including biosimilar medicines, have complex molecular structures and unique manufacturing processes. The development of biosimilar medicines involves many technical challenges and requires distinct regulatory pathways from those applied to generic medicines. For this reason the BIA has been actively engaged in the development of EMA guidelines on biosimilar medicines, including biosimilar monoclonal antibodies, over a period of many years, highlighting the issues to be addressed and ensuring that patient safety remains paramount. With much support from our members and working in partnership with colleagues at the ABPI, we have developed these educational materials to reflect the latest developments in this evolving field. We hope that they will assist healthcare professionals in particular to be aware of, and better understand the challenges of, the introduction of biosimilar medicines to the NHS."
The materials can be downloaded from the ABPI (http://www.abpi.org.uk/our-work/library/medical-disease/Pages/default.aspx) and the BIA websites (http://www.bioindustry.org/newsandresources/position-papers/).
About the BIA
Founded 25 years ago at the infancy of biotechnology, the BIA is the trade association for innovative enterprises involved in
For further information, please go to www.bioindustry.org and twitter.com/BIA_UK.
Most Popular Stories
- National Retail Federation Reduces Sales Forecast
- Desktop, Laptop Setups Still King
- Execs Help Entrepreneurs, Get Chevy Volts
- Demand for Fair Trade Brings Big Opportunity, Clear Conscience
- Shania Twain's Vegas residency ending after 110 shows
- Zillow in Reported $2B Bid for Real Estate Rival Trulia
- Google Confirms $1B Acquisition of Twitch.tv
- Sporty Ford Fiesta Fires on All 3 Cylinders
- Honda' s Accord Plug-in Hybrid Is a Fuel Miser
- Amazon Hiring on Calif.'s Central Coast